niacinamide and sar405838

niacinamide has been researched along with sar405838 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Archibald, HL; Debussche, L; Engelman, JA; Gomez-Caraballo, M; Hata, AN; Ji, F; Jung, J; Lee, JS; Light, M; Rowley, S; Sadreyev, RI; Siddiqui, FM; Sidhu, S; Watters, J	1
de Jonge, M; de Weger, VA; Demers, B; Deutsch, E; Goodstal, S; Hsu, K; Langenberg, MHG; Lolkema, M; Macé, S; Schellens, JHM; Thomas, K; Tuffal, G; Varga, A	1

Trials

1 trial(s) available for niacinamide and sar405838

Article	Year
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. British journal of cancer, 2019, Volume: 120, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; MAP Kinase Kinase Kinases; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins p21(ras); Spiro Compounds; Thrombocytopenia; Tumor Suppressor Protein p53	2019

Article

Year

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.

British journal of cancer, 2019, Volume: 120, Issue:3

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; MAP Kinase Kinase Kinases; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins p21(ras); Spiro Compounds; Thrombocytopenia; Tumor Suppressor Protein p53

2019

Other Studies

1 other study(ies) available for niacinamide and sar405838

Article	Year
Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers. Oncogene, 2017, 11-23, Volume: 36, Issue:47 Topics: A549 Cells; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockdown Techniques; HCT116 Cells; Humans; Indoles; Lung Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Niacinamide; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins p21(ras); RNA Interference; RNA, Small Interfering; Spiro Compounds; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2017

Article

Year

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.

Oncogene, 2017, 11-23, Volume: 36, Issue:47

Topics: A549 Cells; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gene Knockdown Techniques; HCT116 Cells; Humans; Indoles; Lung Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Mutation; Niacinamide; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins p21(ras); RNA Interference; RNA, Small Interfering; Spiro Compounds; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2017